Day One Biopharmaceuticals Completes $2.5B Acquisition by Servier, Delists from Nasdaq

summarizeSummary

Day One Biopharmaceuticals has completed its acquisition by Servier for approximately $2.5 billion, resulting in its delisting from Nasdaq and conversion of shares to cash at $21.50 per share.

check_boxKey Events

• Merger Completion

  Servier successfully acquired Day One Biopharmaceuticals for approximately $2.5 billion, making it a wholly-owned subsidiary. This follows the tender offer that expired on April 22, 2026, with 85.34% of shares tendered.

• Share Conversion

  All outstanding shares were converted into the right to receive $21.50 per share in cash, providing a favorable exit for public shareholders at a price near the 52-week high.

• Delisting & Deregistration

  The company's common stock will be delisted from Nasdaq, and its SEC registration and reporting obligations will be terminated, ending its status as a publicly traded entity.

• Leadership Change

  All former directors and officers of Day One Biopharmaceuticals resigned, with new leadership appointed from Servier to govern the surviving corporation.

auto_awesomeAnalysis

This 8-K formally announces the completion of Servier's tender offer and subsequent merger, making Day One Biopharmaceuticals a wholly-owned subsidiary. Public shareholders will receive $21.50 per share, a price near the 52-week high, providing a favorable exit. The company's shares will be delisted from Nasdaq, and its SEC reporting obligations will terminate, marking the end of its existence as a publicly traded entity. All prior directors and officers have resigned, replaced by Servier's appointees, and key agreements like the ATM program have been terminated. This filing finalizes the corporate actions following the merger completion announced earlier today.